IMUX News & Analysis

Immunic Stock Rated Outperform by Wedbush Analysts

Wedbush has initiated coverage of Immunic, Inc. with an Outperform rating. This rating suggests potential for growth in the company’s stock performance. Immunic is a clinical-stage biopharmaceutical company focused on innovative therapeutics. This move could attract investor interest in Immunic (IMUX), influencing its market performance.